Aetherium Acquisition Corp: Nasdaq/NYSE listing notice — Aetherium Acquisition Corp receives Nasdaq MVLS deficiency notice; 180-day cure period

Aetherium Acquisition Corp

Nasdaq notified Aetherium on May 10, 2023 that its Market Value of Listed Securities fell below $50 million minimum.
Company has until November 6, 2023 to regain compliance; must hold MVLS ≥ $50M for 10 consecutive business days.
If unable to cure, Aetherium may transfer to Nasdaq Capital Market, subject to meeting that market's listing requirements.
Deficiency notice is not a delisting; stock continues trading symbol GMFI on Nasdaq Global Market.
Company will monitor MVLS and consider options to regain compliance; no assurance of success.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aetherium Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

May 10, 2023, Aetherium Acquisition Corp. (the “ Company ”) received written notice from the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50,000,000, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days, or until November 6, 2023, to regain compliance with the minimum MVLS requirement. To regain compliance, t

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001493152-23-018675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.